Who are Experimental: Valacyclovir treatment's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Lonsurf, Dendrid, Ribavirin in Arm 1, Ribavirin "loading" dose given, Acyclovir (ACV), Ribavirin (SCH 018908).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/experimental-valacyclovir-treatment.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Experimental: Valacyclovir treatment — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Experimental: Valacyclovir treatment (Experimental: Valacyclovir treatment) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nucleoside analog antiviral. Area: Infectious Disease / Virology.

marketed Nucleoside analog antiviral Herpesvirus DNA polymerase Infectious Disease / Virology Small molecule Live · refreshed every 30 min

Target snapshot

Experimental: Valacyclovir treatment (Experimental: Valacyclovir treatment) — University of Pittsburgh. Valacyclovir is a prodrug that is converted to acyclovir, which inhibits viral DNA polymerase to prevent herpesvirus replication.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Experimental: Valacyclovir treatment TARGET	Experimental: Valacyclovir treatment	University of Pittsburgh	marketed	Nucleoside analog antiviral	Herpesvirus DNA polymerase
Lonsurf	TIPIRACIL	Taiho Oncology Inc	marketed	Nucleoside Analog Antiviral [EPC]	Thymidine phosphorylase	2015-01-01
Dendrid	IDOXURIDINE	Novartis	marketed	Nucleoside Analog Antiviral	Thymidine kinase, cytosolic	1963-01-01
Ribavirin in Arm 1	Ribavirin in Arm 1	MinaPharm Pharmaceuticals	marketed	Nucleoside analog antiviral	Viral RNA polymerase; IMPDH (inosine monophosphate dehydrogenase)
Ribavirin "loading" dose given	Ribavirin "loading" dose given	Göteborg University	marketed	Nucleoside analog antiviral	Viral RNA-dependent RNA polymerase; IMPDH (inosine monophosphate dehydrogenase)
Acyclovir (ACV)	Acyclovir (ACV)	French National Agency for Research on AIDS and Viral Hepatitis	marketed	Nucleoside analog antiviral	Viral DNA polymerase (herpes simplex virus and varicella-zoster virus)
Ribavirin (SCH 018908)	Ribavirin (SCH 018908)	Merck Sharp & Dohme LLC	marketed	Nucleoside analog antiviral	Viral RNA-dependent RNA polymerase; GTP depletion

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2029-09-22 — Lonsurf · RE46284 · US
2034-06-17 — Lonsurf · 10457666 · US
2034-06-17 — Lonsurf · 9527833 · US
2034-09-05 — Lonsurf · 9943537 · US
2037-02-03 — Lonsurf · 10456399 · US
2037-02-03 — Lonsurf · 10960004 · US

Sponsor landscape (Nucleoside analog antiviral class)

Merck Sharp & Dohme LLC · 3 drugs in this class
Hoffmann-La Roche · 2 drugs in this class
Göteborg University · 2 drugs in this class
Estetra · 1 drug in this class
Padagis LLC · 1 drug in this class
MinaPharm Pharmaceuticals · 1 drug in this class
French National Agency for Research on AIDS and Viral Hepatitis · 1 drug in this class
NYU Langone Health · 1 drug in this class
Assistance Publique - Hôpitaux de Paris · 1 drug in this class
Ain Shams University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Experimental: Valacyclovir treatment — Competitive Intelligence Brief. https://druglandscape.com/ci/experimental-valacyclovir-treatment. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing